OpenURL Connection Search

Select item for more details and to access through your institution.

SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 170, doi. 10.1002/hon.3163_T05
By:
- Pavlovsky, A.;
- Westin, J.;
- Olszewski, A. J;
- Fogliatto, L.;
- Kim, W. S.;
- Shin, H.;
- Leão, D.;
- Jeon, Y.;
- Norasetthada, L.;
- Rego, E.;
- Wu, H.;
- Yin, S.;
- Batlevi, C. L.;
- Pham, S.;
- Penuel, E.;
- Jing, J.;
- Wei, M. C.;
- Budde, L. E.
Publication type:
Article
PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2881
By:
- Kumar, A.;
- Batlevi, C.;
- Drullinsky, P.;
- Grieve, C.;
- Laraque, L.;
- Joseph, A.;
- Mahajan, N.;
- Matasar, M.;
- Straus, D.;
- Zelenetz, A.;
- Hamlin, P.
Publication type:
Article
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.21_2880
By:
- Batlevi, C. L.;
- Salles, G.;
- Tilly, H.;
- Chaidos, A.;
- McKay, P.;
- Phillips, T.;
- Assouline, S.;
- Campbell, P.;
- Ribrag, V.;
- Damaj, G. Laurent;
- Dickinson, M.;
- Jurczak, W.;
- Kaźmierczak, M.;
- Opat, S.;
- Radford, J. R.;
- Schmitt, A.;
- Rajarethinam, A.;
- Shang, G.;
- Morschhauser, F.
Publication type:
Article
MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY.
Published in:
Hematological Oncology, 2019, v. 37, p. 259, doi. 10.1002/hon.68_2630
By:
- Imber, B.S.;
- Palomba, M.L.;
- DeSelm, C.;
- Batlevi, C.;
- Dahi, P.B.;
- Giralt, S.;
- Noy, A.M.;
- Park, J.H.;
- Sauter, C.S.;
- Scordo, M.;
- Shah, G.;
- Sadelain, M.;
- Perales, M.;
- Yahalom, J.
Publication type:
Article
CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA.
Published in:
Hematological Oncology, 2019, v. 37, p. 251, doi. 10.1002/hon.60_2630
By:
- Bobillo, S.;
- Joffe, E.;
- Lavery, J.;
- Noy, A.;
- Palomba, L.;
- Straus, D.J.;
- Kumar, A.;
- Batlevi, C.;
- Horwitz, S.;
- Moskowitz, A.;
- Hamlin, P.;
- Zelenetz, A.;
- Matasar, M.;
- Keudell, G.;
- Sermer, D.;
- Yahalom, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 192, doi. 10.1002/hon.6_2630
By:
- Okosun, J.;
- Bödör, C.;
- Batlevi, C.;
- Nagy, N.;
- Michot, J.;
- Schneider, T.;
- Alizadeh, H.;
- Simon, Z.;
- Vose, J.;
- Younes, A.;
- Ribrag, V.;
- Fitzgibbon, J.;
- Yang, J.;
- Agarwal, S.;
- Newberry, K.J.;
- Michaud, N.R.
Publication type:
Article
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2019, v. 37, p. 331, doi. 10.1002/hon.143_2630
By:
- Sermer, D.;
- Vardhana, S.;
- Batlevi, C.;
- Hamilton, A.;
- Moskowitz, A.;
- Caron, P.;
- Moskowitz, C.;
- Matasar, M.;
- Biggar, E.;
- Leung, E.;
- Yahalom, J.;
- Rademaker, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY.
Published in:
Hematological Oncology, 2019, v. 37, p. 259, doi. 10.1002/hon.68_2630
By:
- Imber, B.S.;
- Palomba, M.L.;
- DeSelm, C.;
- Batlevi, C.;
- Dahi, P.B.;
- Giralt, S.;
- Noy, A.M.;
- Park, J.H.;
- Sauter, C.S.;
- Scordo, M.;
- Shah, G.;
- Sadelain, M.;
- Perales, M.;
- Yahalom, J.
Publication type:
Article
CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA.
Published in:
Hematological Oncology, 2019, v. 37, p. 251, doi. 10.1002/hon.60_2630
By:
- Bobillo, S.;
- Joffe, E.;
- Lavery, J.;
- Noy, A.;
- Palomba, L.;
- Straus, D.J.;
- Kumar, A.;
- Batlevi, C.;
- Horwitz, S.;
- Moskowitz, A.;
- Hamlin, P.;
- Zelenetz, A.;
- Matasar, M.;
- Keudell, G.;
- Sermer, D.;
- Yahalom, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 192, doi. 10.1002/hon.6_2630
By:
- Okosun, J.;
- Bödör, C.;
- Batlevi, C.;
- Nagy, N.;
- Michot, J.;
- Schneider, T.;
- Alizadeh, H.;
- Simon, Z.;
- Vose, J.;
- Younes, A.;
- Ribrag, V.;
- Fitzgibbon, J.;
- Yang, J.;
- Agarwal, S.;
- Newberry, K.J.;
- Michaud, N.R.
Publication type:
Article
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2019, v. 37, p. 331, doi. 10.1002/hon.143_2630
By:
- Sermer, D.;
- Vardhana, S.;
- Batlevi, C.;
- Hamilton, A.;
- Moskowitz, A.;
- Caron, P.;
- Moskowitz, C.;
- Matasar, M.;
- Biggar, E.;
- Leung, E.;
- Yahalom, J.;
- Rademaker, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 420, doi. 10.1002/hon.2440_2
By:
- Nayak, L.;
- Iwamoto, F.M.;
- Ferreri, A.J.;
- Santoro, A.;
- Singer, S.;
- Batlevi, C.;
- Batchelor, T.;
- Rubenstein, J.;
- Johnston, P.;
- Ramchandren, R.;
- Soussain, C.;
- Drappatz, J.;
- Becker, K.;
- Witzens ‐ Harig, M.;
- Illerhaus, G.;
- Herrera, A.;
- Masood, A.;
- Shipp, M.
Publication type:
Article
PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 54, doi. 10.1002/hon.2437_38
By:
- Batlevi, C.;
- Hamlin, P.;
- Matasar, M.;
- Gerecitano, J.;
- Drullinsky, P.;
- Hamilton, A.;
- Straus, D.;
- Horwitz, S.;
- Kumar, A.;
- Moskowitz, C.;
- Moskowitz, A.;
- Zelenetz, A.;
- Ahsanuddin, S.;
- Callan, D.;
- Freidin, B.;
- Porzio, R.;
- Soiffer, J.;
- Copeland, A.;
- Dang, T.;
- Rademaker, J.
Publication type:
Article
DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA.
Published in:
Hematological Oncology, 2017, v. 35, p. 229, doi. 10.1002/hon.2438_92
By:
- Batlevi, C.;
- Alperovich, A.;
- Ni, A.;
- Soumerai, J.;
- Smith, K.;
- Ying, Z.;
- Caron, P.;
- Drullinsky, P.;
- Gerecitano, J.;
- Hamilton, A.;
- Hamlin, P.;
- Horwitz, S.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.;
- Moskowitz, C.;
- Noy, A.;
- Palomba, M.;
- Portlock, C.;
- Sauter, C.
Publication type:
Article
TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 230, doi. 10.1002/hon.2438_93
By:
- Soumerai, J.D.;
- Ni, A.;
- Batlevi, C.;
- Alperovich, A.;
- Bantilan, K.S.;
- Palomba, M.;
- Gerecitano, J.F.;
- Noy, A.;
- Hamlin, P.;
- Moskowitz, C.H.;
- Copeland, A.R.;
- Matasar, M.J.;
- Drullinsky, P.R.;
- Hamilton, A.;
- Horwitz, S.M.;
- Intlekofer, A.M.;
- Kumar, A.;
- Moskowitz, A.;
- Portlock, C.;
- Sauter, C.
Publication type:
Article

Found: 15